Market revenue in 2023 | USD 394.4 million |
Market revenue in 2030 | USD 635.7 million |
Growth rate | 7.1% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Research & Manufacturing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Research & Manufacturing |
Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Roche Holding AG, Qiagen NV, Becton Dickinson & Co, Siemens Healthineers AG ADR, Thermo Fisher Scientific Inc, Hologic Inc, Koninklijke Philips NV, Illumina Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to blood cancer diagnostics market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 66.15% in 2023. Horizon Databook has segmented the Canada blood cancer diagnostics market based on hospitals, outpatient facilities, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
The incidence of blood cancer in Canada has been steadily increasing over the past three decades. It was estimated that 6,000 new cases of leukemia would be diagnosed in Canada every year, and an estimated 4,000 new cases of myeloma would be diagnosed in the year 2022.
To address this growing concern, initiatives such as Myeloma Canada are helping people discover the resources to understand treatment options, tests, and procedures. The blood cancer diagnostics market in Canada is highly competitive, with several major players vying for market share.
Some key companies in this space are Abbott Laboratories, Siemens Healthiness, Sysmex Corporation, and Bio-Rad Laboratories. These companies offer a wide range of diagnostic tests & instruments for various types of blood cancers, such as leukemia, lymphoma, and multiple myeloma.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada blood cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into Canada blood cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account